Zhuhai Shashi Biotechnology
Tumor-infiltrating lymphocyte (til) product being developed by the company for multiple indications.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD300—450m (Dealroom.co estimates Sep 2023.)
China (HQ)
Authorizing premium user...